Targeting signaling pathways in lung cancer therapy.

about

Emerging Roles of MicroRNAs in EGFR-Targeted Therapies for Lung Cancer Histone deacetylases inhibitor trichostatin A increases the expression of Dleu2/miR-15a/16-1 via HDAC3 in non-small cell lung cancer.

P2860

Q26798147-66B890EC-CFCE-4861-AC67-0842986BA720 Q39123831-176C4647-B106-44C4-943B-76EA8E660740

P2860

Targeting signaling pathways in lung cancer therapy.

Item

http://www.wikidata.org/entity/Q46006150

description

2012 nî lūn-bûn

@nan

2012年の論文

@ja

2012年学术文章

@wuu

2012年学术文章

@zh-cn

2012年学术文章

@zh-hans

2012年学术文章

@zh-my

2012年学术文章

@zh-sg

2012年學術文章

@yue

2012年學術文章

@zh

2012年學術文章

@zh-hant

name

Targeting signaling pathways in lung cancer therapy.

@en

Targeting signaling pathways in lung cancer therapy.

@nl

type

Item

label

Targeting signaling pathways in lung cancer therapy.

@en

Targeting signaling pathways in lung cancer therapy.

@nl

prefLabel

Targeting signaling pathways in lung cancer therapy.

@en

Targeting signaling pathways in lung cancer therapy.

@nl

P1476

Targeting signaling pathways in lung cancer therapy.

@en

P2093

William C S Cho

http://www.w3.org/2001/XMLSchema#string

P2860

EGFR expression as a predictor of survival for first-line chemotherapy plus cetuximab in patients with advanced non-small-cell lung cancer: analysis of data from the phase 3 FLEX study.

Afatinib for patients with lung adenocarcinoma and epidermal growth factor receptor mutations (LUX-Lung 2): a phase 2 trial.

Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study

Phase II study of everolimus (RAD001) in previously treated small cell lung cancer.

Clinical course of advanced non-small-cell lung cancer patients experiencing hypertension during treatment with bevacizumab in combination with carboplatin and paclitaxel on ECOG 4599.

Efficacy of bevacizumab plus erlotinib versus erlotinib alone in advanced non-small-cell lung cancer after failure of standard first-line chemotherapy (BeTa): a double-blind, placebo-controlled, phase 3 trial.

Phase 1 and pharmacokinetic study of everolimus, a mammalian target of rapamycin inhibitor, in combination with docetaxel for recurrent/refractory nonsmall cell lung cancer.

A novel sLRP6E1E2 inhibits canonical Wnt signaling, epithelial-to-mesenchymal transition, and induces mitochondria-dependent apoptosis in lung cancer.

Distinct patterns of cytokine and angiogenic factor modulation and markers of benefit for vandetanib and/or chemotherapy in patients with non-small-cell lung cancer.

Plasma cytokine and angiogenic factor profiling identifies markers associated with tumor shrinkage in early-stage non-small cell lung cancer patients treated with pazopanib

P304

107-111

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

editorial

P356

10.1517/14728222.2013.729043

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2012-12-11T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

233899617

http://www.w3.org/2001/XMLSchema#string

P698

23231077

http://www.w3.org/2001/XMLSchema#string

Targeting signaling pathways in lung cancer therapy.

about

P2860

P2860

Targeting signaling pathways in lung cancer therapy.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P577

P5875

P698

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P577

P5875

P698